OncoSec Medical Appoints Jean S. Campbell, Ph.D. as Executive Director of Research and Development
April 21 2014 - 6:02AM
Business Wire
University of Washington Professor to Oversee
Expanded R&D Operations at Icogenex Bioincubator R&D
Facility in Seattle, Washington.
OncoSec Medical Inc. (OTCQB: ONCS), a company developing its
ImmunoPulse DNA-based immunotherapy to treat solid tumors, has
appointed Jean S. Campbell, Ph.D. as Executive Director of Research
and Development, a newly created position. Dr. Campbell, an
Associate Professor in the Department of Pathology in the School of
Medicine at the University of Washington, Seattle, will leverage
her considerable expertise in cancer biology and signal
transduction to investigate mechanisms of immune tolerance in
cancer.
“Dr. Campbell brings to the OncoSec team an extensive research
background and a deep understanding of cancer biology and tumor
progression,” said Punit Dhillon, President and CEO. “We are
thrilled to have her join us at this pivotal moment in OncoSec’s
history. Hiring Dr. Campbell and building OncoSec’s internal
capabilities for proprietary drug discovery and preclinical
development are key steps forward to delivering a differentiated
immune-oncology pipeline.”
Robert Pierce, M.D., Chief Medical Officer, said, “Until now, we
have exclusively focused on driving our existing clinical trials
forward. Given the success of those trials and the largely untapped
promise of ImmunoPulse as a platform for delivering
immunomodulatory DNA constructs, we feel that now is the right time
in OncoSec’s evolution to expand our bevy of drug candidates. Dr.
Campbell and her team are well positioned to increase our research
and development (R&D) efforts through this critical period, as
we look at near-term data from our Phase II programs and
advancements of our ImmunoPulse programs and platform.”
Prior to joining OncoSec Medical, Dr. Campbell was liaison for
the Northwest Liver Research Program and a principal investigator
of an R01-funded research laboratory. She played an active role in
developing the graduate curriculum in translational aspects of
disease mechanisms and served as course director for multiple
courses, mentoring numerous graduate and undergraduate
students.
Dr. Campbell completed her post-doctoral training at the
University of Washington in Seattle with Dr. Bennett Shapiro,
currently a Senior Partner and Chairman of the Board at PureTech
Ventures, and the late Dr. Edwin Krebs, recipient of the Nobel
Prize in Medicine or Physiology in 1992. She received her Ph.D.
from the University Wisconsin in Madison and completed her
undergraduate studies in chemistry at The College of Wooster in
Ohio.
She is the co-author of more than 70 peer-reviewed journal
articles and book chapters, and a reviewer for numerous scientific
journals and grant review panels.
Dr. Campbell said, “Immunotherapy holds great promise as a
therapeutic modality for oncology and chronic diseases. We now seek
to better understand the basic mechanisms of immune modulation
within the tumor microenvironment and its capacity to affect
systemic anti-tumor immune responses.”
Separately, OncoSec announced the expansion of its R&D
capabilities with dedicated laboratory space at the Icogenex
Bioincubator in Seattle. OncoSec currently employs six
scientists between Seattle and San Diego, and the company is
projecting to hire at least 15 new R&D employees over the next
year. The laboratory gives OncoSec a temporary but scalable space
with access to a state-of-the-art facility with both molecular and
cellular biology capabilities.
“We are excited about this expansion of our capacity and
bandwidth in R&D,” said Punit Dhillon. “We have built close
relationships with some of the most prestigious academic research
centers, such as University of Washington and the Fred Hutchinson
Cancer Research Center, and this facility will allow us to offer
even more direct access to these partners. That, coupled with the
robust life sciences cluster in the region, makes Seattle a perfect
fit for our business. Now, with screening new targets to
pre-clinical development capabilities available in-house, OncoSec
will truly be able to expand our R&D pipeline.”
About OncoSec Medical Inc.
OncoSec Medical Inc. is a biopharmaceutical company developing
its ImmunoPulse immunotherapy to treat solid tumors. OncoSec
Medical's core technology leverages a proprietary electroporation
platform to enhance the local delivery and uptake of
IL-12 and other DNA-based immune-modulating agents. Clinical
studies of ImmunoPulse have demonstrated an acceptable safety
profile and preliminary evidence of anti-tumor activity in the
treatment of various skin cancers, as well as the potential to
initiate a systemic immune response without the systemic toxicities
associated with other treatments. OncoSec's clinical programs
currently include three Phase 2 trials targeting metastatic
melanoma, Merkel cell carcinoma and cutaneous T-cell lymphoma
(http://clinicaltrials.gov/ct2/results?term=oncosec&Search=Search).
As the company continues to evaluate ImmunoPulse in these
indications, it is also investigating additional indications and
combination therapeutic approaches. For more information, please
visit www.oncosec.com.
This press release contains forward-looking statements within
the meaning of the U.S. Private Securities Litigation Reform Act of
1995. Any statements in this release that are not historical facts
may be considered such “forward-looking statements.”
Forward-looking statements are based on management’s current
preliminary expectations and are subject to risks and
uncertainties, which may cause our results to differ materially and
adversely from the statements contained herein. Some of the
potential risks and uncertainties that could cause actual results
to differ from those predicted include our ability to raise
additional funding, our ability to acquire, develop or
commercialize new products, uncertainties inherent in pre-clinical
studies and clinical trials, unexpected new data, safety and
technical issues, competition, and market conditions. These and
additional risks and uncertainties are more fully described in
OncoSec Medical’s filings with the Securities and Exchange
Commission. Undue reliance should not be placed on forward-looking
statements, which speak only as of the date they are made. OncoSec
Medical disclaims any obligation to update any forward-looking
statements to reflect new information, events or circumstances
after the date they are made, or to reflect the occurrence of
unanticipated events.
Investor Relations:OncoSec Medical Inc.Veronica Vallejo,
CFO855-662-6732investors@oncosec.com
OncoSec Medical (NASDAQ:ONCS)
Historical Stock Chart
From Mar 2024 to Apr 2024
OncoSec Medical (NASDAQ:ONCS)
Historical Stock Chart
From Apr 2023 to Apr 2024